At InCare, we screen for health history, lifestyle, and goals before crafting a plan
The following sources give you the unfiltered picture - clinical evidence, regulatory context, and safety data straight from the organizations that publish it: FDA.gov - official FDA communications on compounded semaglutide, tirzepatide, and the 503B Bulks List proposal (April 30, 2026)
10.1007/s10549-011-1925-0 Breast Cancer Res
Understanding these key differences can help you make an informed decision about effective weight management approaches that align with your health goals
Whether the triple agonist mechanism translates into meaningfully greater clinical benefit over dual agonists in humans has not yet been established in head-to-head trials
Originally, severe gastrointestinal issues were considered rare